News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,899 Results
Type
Article (13696)
Company Profile (100)
Press Release (250103)
Section
Business (88010)
Career Advice (464)
Deals (15340)
Drug Delivery (66)
Drug Development (36576)
Employer Resources (49)
FDA (6280)
Job Trends (6193)
News (150156)
Policy (14031)
Tag
Academia (437)
Alliances (23196)
Alzheimer's disease (375)
Approvals (6302)
Artificial intelligence (86)
Bankruptcy (146)
Best Places to Work (4370)
Breast cancer (69)
Cancer (501)
Cardiovascular disease (52)
Career advice (406)
Cell therapy (72)
Clinical research (30728)
Collaboration (273)
Compensation (114)
COVID-19 (753)
C-suite (90)
Data (497)
Diabetes (66)
Diagnostics (1308)
Drug discovery (46)
Drug pricing (60)
Earnings (31776)
Events (37172)
Executive appointments (309)
FDA (6595)
Funding (171)
Gene therapy (84)
GLP-1 (320)
Government (1281)
Healthcare (3554)
Infectious disease (780)
Inflammatory bowel disease (52)
Interviews (58)
IPO (5869)
Job creations (2050)
Job search strategy (372)
Layoffs (175)
Legal (3427)
Lung cancer (71)
Manufacturing (122)
Medical device (1268)
Medtech (1270)
Mergers & acquisitions (9612)
Metabolic disorders (210)
Neuroscience (519)
NextGen: Class of 2025 (1585)
Non-profit (592)
Northern California (600)
Obesity (122)
Opinion (116)
Patents (86)
People (28743)
Pharmaceutical (64)
Phase I (7997)
Phase II (12997)
Phase III (11667)
Pipeline (272)
Policy (52)
Postmarket research (1401)
Preclinical (3187)
Radiopharmaceuticals (117)
Rare diseases (141)
Real estate (2632)
Regulatory (9998)
Research institute (563)
Resumes & cover letters (55)
Southern California (594)
Startups (1625)
United States (5950)
Vaccines (132)
Weight loss (88)
Date
Last 7 days (232)
Last 30 days (990)
Last 365 days (12354)
2025 (1725)
2024 (12500)
2023 (14250)
2022 (19557)
2021 (20070)
2020 (19034)
2019 (14893)
2018 (11717)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (312)
Arizona (46)
Asia (19994)
Australia (2589)
California (1431)
Canada (790)
China (185)
Colorado (60)
Connecticut (61)
Europe (39152)
Florida (250)
Illinois (165)
Indiana (113)
Japan (72)
Kansas (53)
Maryland (213)
Massachusetts (1215)
Minnesota (78)
New Jersey (608)
New York (404)
North Carolina (340)
Northern California (600)
Pennsylvania (361)
South America (500)
Southern California (594)
Texas (185)
Virginia (57)
Washington State (99)
263,899 Results for "braeburn pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Braeburn Announces Publication of a Post Hoc Analysis of Data from Patients Using Fentanyl Treated with BRIXADI in a Phase 3 Efficacy and Safety Study
Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open.
June 25, 2024
·
12 min read
FDA
Braeburn’s Long-Acting Brixadi Receives FDA Clearance to Treat Opioid Use Disorder
The FDA approved Braeburn Pharmaceuticals’ new buprenorphine treatment option with extended-release medication that could pave the way for greater patient compliance.
May 25, 2023
·
3 min read
·
Lisa Munger
Pharm Country
Braeburn’s BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder
Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD).
May 23, 2023
·
12 min read
Biotech Beach
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.
June 13, 2024
·
9 min read
Press Releases
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
December 12, 2024
·
5 min read
Business
Altruix Approved to Dispense Brixadi® for Moderate to Severe Opioid Use Disorder
Altruix announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).
August 17, 2023
·
2 min read
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has resubmitted the New Drug Application (NDA) for Brixadi 1 (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe opioid use disorder to the US Food and Drug Administration (FDA).
June 15, 2021
·
1 min read
Pharm Country
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Braeburn announces that today the New Drug Application (NDA) for BRIXADI was resubmitted to the U.S. Food and Drug Administration (FDA).
June 15, 2021
·
2 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Eupraxia Pharmaceuticals Announces CFO Succession
February 18, 2025
·
8 min read
1 of 26,390
Next
